• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

BD wins patent fight against Baxter over drug-transfer system

August 24, 2022 By Sean Whooley

BD BaxterBD (NYSE:BD) picked up a legal victory in a patent spat with Baxter (NYSE:BAX) over a system for moving drugs.

A federal judge in Chicago ruled that BD’s PhaSeal system for transporting hazardous drugs between syringes and vials doesn’t infringe two patents belonging to Baxter.

U.S. District Judge Joan Lefkow granted BD summary judgment on two patent claims and resolved all claims in its favor. She denied BD’s motion for summary judgment on willfulness and damages as moot. She also denied Baxter’s motion for partial summary judgment as moot, terminating the case.

Baxter had alleged that the combination of two components of the PhaSeal system — the “protector” and “injector” — form a device that infringes on three of its patents, each entitled “Sliding Reconstitution Device With Seal.”

Lefkow said in the decision that the PhaSeal system doesn’t violate Baxter’s patent rights in the “reconstitution” device for diluting liquid drugs. The judge concluded that the patents weren’t violated because components for the PhaSeal system aren’t purchased in an infringing manner as they can be used for purposes beyond “reconstitution.”

Reuters first reported on the decision yesterday. According to the outlet, the suit dates back to 2017 and BD and its CareFusion subsidiary still face a separate patent case from Baxter regarding the Alaris infusion pump system. Alaris faces its own issues, mostly over recalls, with the most recent setback coming in the form of a shareholder lawsuit against BD over communications of company performance amid the recalls.

Filed Under: Drug-Device Combinations, Featured, Legal News, Pharmaceuticals Tagged With: Baxter, BD

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS